CNR2 and cancer: In contrast, CB2 immunoreactivity was documented in 72% of human breast tissues [128], and is present in 91% of ErbB2-positive cancer tissues (in contrast to CB1 receptor), suggesting a relationship between CB1 receptor and the ErbB2-positive cancer cell phenotype [128].